VivoSeq
Other

LAL

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

LAL is an early-stage landscape with 0 programs across 2 companies. The most active players are Gilead, BioMarin Pharmaceutical.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

25/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalBioMarin Pharmaceutical logo

BioMarin Pharmaceutical

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Terminated2 · 33%
Withdrawn1 · 17%
Unknown status1 · 17%
Not yet recruiting1 · 17%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay
Not yet recruiting·SState University of New York - Upstate Medical University·N/A·NCT07220031·8 enrolled
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Completed·BioMarin Pharmaceutical logoBioMarin Pharmaceutical·Phase 3·NCT00225615·100 enrolled
OCT-guided LALAK for KCN
Terminated·OOregon Health and Science University·N/A·NCT01901614·5 enrolled
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Terminated·Gilead logoGilead·Phase 1/2·NCT01090414·202 enrolled
LALAK for Opacities
Withdrawn·OOregon Health and Science University·N/A·NCT01901601
The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.
Unknown status·—·N/A·NCT03260634·92 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)